Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q2- Text added to 2023 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
New words:
adequacy, adjudication, creatinine, deliverable, East, Evive, highlighted, Ironwood, Issuer, Middle, mix, mofetil, mycophenolate, Nephrology, Nkarta, protein, PTA, Sanofi, Unregistered, unvested, UPCR, urine, Yifan
Removed:
Amgen, Boehringer, fast, Ingelheim, Squibb
Valuein 2023 Q2 filing- Value in 2023 Q3 filing
Original filings
Filing view